Drug Target Review

JULY 17, 2024

While current polyclonal antibody (pAb) therapies are derived from plasma, GigaGen has developed single-cell discovery and development platforms to produce diverse and potent recombinant pAb therapies that are made in the laboratory. It aims to clear HBsAg, to support HBV-specific immune responses and to achieve functional cure.

Immune Response 59

Immune Response Therapies Laboratories Vaccine 59

The Pharma Data

APRIL 15, 2022

About the Pfizer-BioNTech Laboratory Study. In December 2021, Pfizer and BioNTech announced the companies would test a third 3 µg dose given at least two months after the second dose in children under age 5 and a third dose of the 10 µg formulation in children 5 to under 12 years of age.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

Creative Biolabs

JULY 12, 2020

Professor Florian Klein, the paper’s corresponding author, explained, “our goal is to better understand the immune response to SARS-CoV-2 and to identify highly potent antibodies that can be used to prevent and treat COVID-19.” They are expected to enter clinical development later this year.

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

Drug Target Review

SEPTEMBER 9, 2024

Additionally, ‘1104 increases the number of activated regulatory T and B cells, which help modulate the immune response and maintain immune tolerance, preventing the immune system from entering overdrive. As such, ‘1104 uniquely affects both the effector and regulatory arms of the immune response.

Disease 64

Disease Immune Response Clinical Trials Treatment 64

The Pharma Data

MARCH 31, 2022

The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. Fauci, M.D. Investigators aim to have initial findings available by August 2022.

Clinical Trials 52

Clinical Trials Trials Immune Response Vaccine 52

Codon

AUGUST 27, 2024

For example, many different filoviruses attack white blood cells and cause similar innate immune responses , which makes it difficult to identify a particular species from only their DNA. At least nine laboratories outside the U.S. But these technologies continue to improve along both axes.

DNA 102

DNA Laboratories Hospitals Virus 102

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

PLOS: DNA Science

MAY 16, 2024

That’s thanks to accelerated genome sequencing technologies, expanded laboratory capabilities, and interacting infrastructure on a global level. • identifies parts of the virus to target to provoke an immune response from a vaccine. • reveals viral vulnerability to inspire novel treatments.

Virus 98

Virus DNA RNA Science 98

Broad Institute

JUNE 27, 2024

ZFPs are also common in human cells, meaning they are less likely to trigger an immune response against themselves than the bacterial Cas9. However, with a strong therapy design and promising laboratory results in hand, the researchers have good reason to be hopeful.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Target Review

NOVEMBER 6, 2023

For example, combining IO agents with ADCs to mount a two-pronged attack against cancer by activating an anti-cancer immune response and directly killing cancer cells may drive stronger and more durable responses in the clinic.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

SEPTEMBER 14, 2020

Monoclonal antibodies, which are potent, laboratory-made antibodies, will be given to about 2,000 people to see if they are effective against coronavirus. This is then given to patients, immediately boosting their immune response. Illustration of antibodies attacking the coronavirus. Follow Rebecca on Twitter.

Trials 52

Trials Immune Response Virus Vaccine 52

Codon

JULY 14, 2024

As stored blood was often needed expediently in response to traumas, these early military blood banks only carried blood from the universally accepted O group of donors to circumvent the need for blood-typing in urgent situations. Karl Landsteiner in his New York laboratory. 5 There is a caveat in the linked studies, however.

Production 141

Production Clinical Trials Trials Therapies 141

Drug Target Review

JANUARY 9, 2024

Prior to the new study, the laboratories of Dr Michael Levin, Vannevar Bush Professor of Biology at Tufts University School of Arts & Sciences, and Dr Josh Bongard at the University of Vermont, created multicellular biological robots from frog embryo cells, named xenobots.

Laboratories 59

Laboratories Immune Response DNA Science 59

PerkinElmer

JANUARY 25, 2023

Laboratory professionals in all areas of science have experienced significant changes in recent years, and 2022 was no exception. Experts in the diagnostics and life sciences industry look back on 2022 and lend their insights on the major trends and technologies shaping laboratories in 2023. With the expanding territory of I.

Science 52

Science Laboratories Immune Response Disease 52

The Pharma Data

JANUARY 21, 2021

The compound was developed in the laboratory of Richard Childs, chief of the Laboratory of Transplantation Immunotherapy with the National Heart, Lung, and Blood Institute (NHLBI). It hopes to raise $125 million in the IPO that it announced on January 19.

Immune Response 52

Immune Response Laboratories Trials Therapies 52

The Pharma Data

OCTOBER 23, 2020

In this week’s update, Pharma IQ share updates from WHO’s solidarity clinical trial and a new treatment option in Europe to help clinicians receive a better understand the Covid-19 patient immune response. WHO concludes subcutaneous treatment is ineffective in hospitalized Covid-19 patients.

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

Drug Target Review

SEPTEMBER 8, 2023

.” Several years ago, Cheroutre and her colleagues released research findings demonstrating that retinoic acid (RA), derived from vitamin A, triggers the activation of nuclear RARα and fosters gene expression that is critical for the differentiation of regulatory T cells with suppressive abilities, ultimately dampening immune responses.

Regulations 98

Regulations Research DNA Immune Response 98

Drug Target Review

FEBRUARY 5, 2024

Adult laboratory mice heal injuries with scar tissue, but spiny mice have the unique ability to regrow lost skin and regenerate musculoskeletal tissues in their body. A study 1 from Seifert’s group, published last year, demonstrated how ERK signalling acts as a crucial switch balancing the healing response. Wiley Online Library.

Laboratories 59

Laboratories Immune Response RNA Regulations 59

NIH Director's Blog: Drug Development

MAY 21, 2020

The research team, led by Yan Wu, Capital Medical University, Beijing, first isolated the pair of antibodies in the laboratory, starting with white blood cells from the patient. In laboratory experiments, the researchers used the RBD snippet as “bait” to attract antibody-producing B cells in a blood sample obtained from the COVID-19 survivor.

Virus 52

Virus Vaccine Laboratories Science 52

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

JUNE 17, 2022

Therefore, we are pretty confident that they represent premium candidates for pre-exposure prophylaxis in immunocompromised patients,” says Hugo Mouquet, head of the Laboratory of Humoral Immunology at the Institut Pasteur, who led the study.

Immune Response 52

Immune Response Clinical Trials Laboratories Engineering 52

The Pharma Data

AUGUST 16, 2020

Dr Hindley, whose PhD was in T cells, said: “They can live for a long time after the infection and give you that immune response. ” Currently only a handful of laboratories across the world are equipped to test for T cells, and it is a “laborious” process with a lot of complex machinery, Dr Hindley said. .

Virus 52

Virus Vaccine Immune Response Government 52

The Pharma Data

JANUARY 19, 2021

The compound was developed in the laboratory of Richard Childs, chief of the Laboratory of Transplantation Immunotherapy with the National Heart, Lung, and Blood Institute (NHLBI). It hopes to raise $125 million in the IPO. In January 2020, it raised $69 million in Series D, bringing the then-total up to $150 million.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

NOVEMBER 27, 2020

Iceni Diagnostics’ testing device is currently being tested in care homes in Wales and at Cambridge Clinical Laboratories , which carries out antigen (PCR) Covid testing for Nation Health Service England. This new approach could potentially result in a more universal detection technique, crucial in early diagnostics of virus outbreaks.”.

Virus 52

Virus Vaccine International Immune Response 52

Drug Target Review

OCTOBER 10, 2024

In the context of preclinical research, using healthy cells to study disease-specific mechanisms, cell-cell interactions, and immune responses can result in faulty data, missed therapeutic targets, and unanticipated immune responses.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

The Pharma Data

MARCH 16, 2021

This research use only laboratory test can be used to help scientists track mutation prevalence and to assess any potential impact on diagnostics, vaccines and therapeutics, providing crucial insight for healthcare systems in making appropriate measures to combat COVID-19. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1).

Clinical Trials 52

Clinical Trials Laboratories Virus Vaccine 52

The Pharma Data

JANUARY 17, 2021

One consideration in using syngeneic models is that some drug candidates can cause a negative immune response not seen in humans. These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor.

Immune Response 40

Immune Response Pharmacokinetics Engineering Licensing 40

The Pharma Data

OCTOBER 26, 2020

based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the U.K.-based The drug is an orally active caspase inhibitor.

Vaccine 52

Vaccine FDA Approval Clinical Trials FDA 52

The Pharma Data

APRIL 22, 2023

It can work well, but we also want to trigger the immune system’s ability to remove the virus, which can be done through opsonizing antibodies that mark the virus so it can be eliminated,” explains Pontus Nordenfelt, associate professor and researcher in infectious medicine who led the study, published in PNAS.

Virus 40

Virus Immune Response Laboratories Doctors 40

Drug Target Review

DECEMBER 5, 2024

Determining the ratio of full, partially filled, and empty capsids is considered a Critical Quality Attribute (CQA) for AAV gene therapy products, and is a factor that must be monitored and controlled, as higher empty capsid contents in gene therapies poses risks of triggering an immune response and adverse events in the clinic (Figure 1).

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

SEPTEMBER 17, 2020

The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

APRIL 22, 2023

Instead of targeting the constantly mutating spike protein, the team at Evaxion Biotech designed a vaccine that included 17 epitopes from various proteins of SARS-CoV-2 that are recognized by the immune system. These epitopes elicit an immune response from a broad selection of T cells, ensuring a sustained coverage of future variants.

Vaccine 40

Vaccine Virus Laboratories Immune Response 40

The Pharma Data

JANUARY 13, 2021

The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan. More than 90% of participants mounted an immune response within a month, and all had levels of neutralizing antibodies by day 57. WEDNESDAY, Jan. vaccination efforts.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

New Drug Approvals

APRIL 8, 2025

By blocking the recruitment to the tumor microenvironment (TME) and activity of CSF1R-dependent tumor-associated macrophages (TAMs), vimseltinib inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and anti-tumor T-cell immune responses, which inhibits the proliferation of tumor cells.

FDA Approval 57

FDA Approval FDA Clinical Development Treatment 57

The Pharma Data

DECEMBER 28, 2020

Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. For more information about the Company, please visit [link].

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52